Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice | Zendy

Aaron P. Mitchell | Zendy; Michael R. Harrison | Zendy; Mark S. Walker | Zendy; Daniel J. George | Zendy; Amy P. Abernethy | Zendy; Bradford R. Hirsch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice

Author(s) -

Aaron P. Mitchell,

Michael R. Harrison,

Mark S. Walker,

Daniel J. George,

Amy P. Abernethy,

Bradford R. Hirsch

Publication year - 2015

Publication title -

journal of oncology practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.555

H-Index - 60

eISSN - 1935-469X

pISSN - 1554-7477

DOI - 10.1200/jop.2015.004929

Subject(s) - medicine , sunitinib , pazopanib , temsirolimus , sorafenib , clinical trial , renal cell carcinoma , oncology , apatinib , cancer , kidney cancer , hepatocellular carcinoma , apoptosis , biochemistry , chemistry , protein kinase b , discovery and development of mtor inhibitors

Although narrow eligibility criteria improve the internal validity of clinical trials, they may result in differences between study populations and real-world patients, threatening generalizability. Therefore, we evaluated whether patients treated for metastatic renal cell cancer (mRCC) in routine clinical practice are similar to those enrolled onto clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research